TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Cogent Biosciences ( (COGT) ) is now available.
On November 18, 2025, Cogent Biosciences completed a public offering of $230 million in Convertible Senior Notes due 2031. This financial move is designed to strengthen the company’s capital structure and potentially enhance its market position by providing flexibility for future growth and operations. The Notes, which are unsecured and senior obligations, offer conversion options under specific conditions and are subject to redemption and repurchase terms. The offering could impact stakeholders by influencing the company’s financial strategies and market dynamics.
The most recent analyst rating on (COGT) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Cogent Biosciences stock, see the COGT Stock Forecast page.
Spark’s Take on COGT Stock
According to Spark, TipRanks’ AI Analyst, COGT is a Underperform.
Cogent Biosciences is currently facing significant financial difficulties, with no recent revenue, ongoing operating losses, and negative cash flows. The technical analysis indicates a bearish trend, and the valuation is unattractive due to a negative P/E ratio and absence of dividends. These factors contribute to the lowest overall stock score, highlighting substantial risks for investors.
To see Spark’s full report on COGT stock, click here.
More about Cogent Biosciences
Cogent Biosciences, Inc. operates within the biotechnology industry, focusing on the development of precision therapies for genetically defined diseases. The company primarily targets the treatment of rare genetic disorders and cancer, aiming to address unmet medical needs in these areas.
Average Trading Volume: 2,730,988
Technical Sentiment Signal: Buy
Current Market Cap: $5.1B
For a thorough assessment of COGT stock, go to TipRanks’ Stock Analysis page.